UIC receives $3 million to study prostate cancer risk factors

February 27, 2009

Researchers at the University of Illinois at Chicago's Institute for Health Research and Policy have been awarded a five-year, $3 million grant from the National Cancer Institute to study the link between body fat and prostate cancer progression.

Recent studies have found that obese men with prostate cancer have a higher likelihood of developing progressive or fatal disease regardless of their tumor grade and stage at diagnosis.

The UIC researchers plan to identify the biological factors responsible for poorer outcomes among obese patients, says Dr. Vincent Freeman, assistant professor of epidemiology at the UIC School of Public Health and principal investigator of the project.

The findings should lead to new approaches to preventing prostate cancer recurrence or progression after treatment that could involve drug therapies, lifestyle changes, or both, Freeman said.

Freeman's team will enroll approximately 500 men from Chicago-area medical centers who have been diagnosed with clinically early-stage prostate cancer and who are candidates for curative therapy with surgery.

Body fat will be quantified at the time of diagnosis and one year after surgery using standard body-size measurements such as waist circumference and body mass index, and body composition measurements using X-rays to measure the relative amounts of bone, body water, and body fat.

Data will also be collected for the patient's body-weight history, diet, physical activity level, general health and socio-demographic background.

At the time of surgery, the researchers will also collect prostate tissue and fat tissue from the region of the prostate gland for a series of biochemical and molecular studies, Freeman said. They will measure fatty acids and their metabolites; the activity of a signaling pathway called the insulin-like growth factor axis; inflammatory factors that are produced by fat cells; and metabolites of male hormones. The tests "will determine whether the activity of certain metabolic pathways explains the association between body fatness and prostate cancer recurrence," Freeman said.

Patients will be followed for two years with periodic measurements of prostate-specific antigen, a protein produced by the prostate gland. Those with prostate cancer recurrence will be identified by an increasing PSA. Typically, the PSA should remain in an undetectable range following surgery for prostate cancer.
-end-
UIC ranks among the nation's top 50 universities in federal research funding and is Chicago's largest university with 25,000 students, 12,000 faculty and staff, 15 colleges and the state's major public medical center. A hallmark of the campus is the Great Cities Commitment, through which UIC faculty, students and staff engage with community, corporate, foundation and government partners in hundreds of programs to improve the quality of life in metropolitan areas around the world.

For more information about UIC, visit www.uic.edu

University of Illinois at Chicago

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.